Initiate combination MAD trials of an NBD1 stabilizer with a complementary modulator
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 20 Mar 2025
- Due
- 31 Dec 2025
- Delivered
- August 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“On track to... initiate... combination MAD trials of an NBD1 stabilizer with a complementary modulator in healthy volunteers in the second half of 2025”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 1 dual combination trial of SION-451 with SION-2222 and SION-109 in August 2025, successfully meeting the commitment to initiate these trials in the second half of 2025.
-
A Sionna Therapeutics, Inc. 8-K filed 2026-03-02
“In August 2025, Sionna announced the initiation of the Phase 1 trial (NCT07035990) evaluating SION-451 in proprietary dual combinations with SION-2222 (galicaftor), a transmembrane domain 1 (TMD1)-directed CFTR corrector, and with SION-109” ✓ confirmed on the page
Market reaction: the shares moved -5.3% against the S&P 500 over the three sessions around the disclosure (27 Feb 2026 to 4 Mar 2026). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Combination MAD trials
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Sionna Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-SION-001950 · Corrections policy